The xGen Acute Myeloid Leukemia (AML) Cancer Panel v1.0 comprises 11,731 xGen Lockdown Probes, spanning 1.19 Mb of the human genome, for targeted enrichment of >260 genes associated with AML, to provide more efficient detection of disease-causing mutations.
The xGen Acute Myeloid Leukemia Cancer Panel v1.0 is comprised of individually synthesized and quality controlled xGen Lockdown Probes. The panel consists of 11,731 xGen Lockdown Probes targeting empirically derived regions within 260 genes. The targets were defined by whole genome and exome sequencing of 200 AML patients.
Table 1. Frequently researched genes included in the xGen AML Cancer Panel.*
* The panel does not target every exon in each gene, but targets all regions found to be mutated in the TCGA study (N Engl J Med, 368(22):2059–2074). For a complete list of genes, click here.
Figure 1. Excellent coverage uniformity obtained with xGen Lockdown AML Cancer Panel. Greater than 0.2 x mean coverage is observed for >98% of targets. Libraries were prepared using the Illumina TruSeq® LT chemistry and sequenced on a MiSeq® system using 250 x 250 paired-end reads. A cumulative of 31.8M reads was generated for all four samples.
Figure 2. Deep coverage of targeted regions using xGen AML Cancer Panel. Four TruSeq genomic DNA libraries were enriched using the xGen Acute Myeloid Leukemia Cancer Panel and sequenced on a MiSeq system using 250 x 250 paired-end reads. A total of 31.8M reads were generated. In all samples, there was >1X coverage for 99.8% of targets and >30X coverage for 99.2–99.4% of targets.
Figure 3. Excellent reproducibility obtained with xGen AML Cancer Panel. Multiplexed samples prepared with Illumina TruSeq libraries were sequenced on the MiSeq sequencing platform using 250 x 250 paired-end reads. A comparison of probe-by-probe target coverage between two samples showed excellent reproducibility, with an R2 value of 0.9831.